A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Dec 2017

At a glance

  • Drugs Lanabecestat (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms DAYBREAK; DAYBREAK-ALZ
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 Aug 2017 Planned End Date changed from 1 Apr 2021 to 1 Mar 2021.
    • 25 Aug 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Sep 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top